by Portfolio Grader | October 2, 2013 9:45 am
This week, seven Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
This week, ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) gets a higher grade this week, advancing from a C last week to a B. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
Array BioPharma (NASDAQ:ARRY) boosts its rating from a C to a B this week. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. With a price of $6.44, it is above the 50-day moving average of $6.15. Shares of the stock have been changing hands at an unusually rapid pace, four times the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. Shares of CLDX have increased 60.8% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of CLDX stock.
The rating of Insmed Incorporated (NASDAQ:INSM) moves up this week, rising from a C to a B. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. The stock’s price of $15.98 is above the 50-day moving average of $13.26. For more information, get Portfolio Grader’s complete analysis of INSM stock.
This week, Neuralstem, Inc. (AMEX:CUR) pushes up from a C to a B rating. Neuralstem is a biotherapeutics company utilizing its Human Neural Stem Cell technology to develop cures for diseases of the CNS. For more information, get Portfolio Grader’s complete analysis of CUR stock.
Arrowhead Research Corporation (NASDAQ:ARWR) earns a B this week, jumping up from last week’s grade of C. Arrowhead Research is a nanotechnology holding company that forms, acquires, and operates subsidiaries commercializing innovative nanotechnologies. Investors have pushed the stock price up 41.4% over the past month. For more information, get Portfolio Grader’s complete analysis of ARWR stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/10/7-biotechnology-stocks-to-buy-now-aria-nbix-arry/
Short URL: http://invstplc.com/1ftPPLw